etanidazole has been researched along with Benign Neoplasms in 44 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When misonidazole (MISO) was introduced into clinical trials there were great expectations that the cure rate of many tumors would be dramatically increased." | 3.75 | Hypoxic cell radiosensitizers: expectations and progress in drug development. ( Coleman, CN, 1985) |
| " The plasma half-life was 11." | 2.70 | Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. ( Covey, JM; Evans, SM; Hahn, SM; Koch, CJ; McKenna, WG; Rockwell, K, 2001) |
| " Effective modulatory doses of etanidazole could not be given with acceptable toxicity using this schedule." | 2.69 | Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. ( Antman, KH; Ayash, LJ; Coleman, N; Elias, AD; Frei, E; Ibrahim, J; McCauley, M; Mills, L; Schnipper, L; Schwartz, G; Teicher, BA; Warren, D; Wheeler, C, 1998) |
| "Etanidazole was given via intravenous infusion over 15 minutes, followed within 20 to 30 minutes by intraoperative radiation therapy." | 2.67 | RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies. ( Buswell, L; Coleman, CN; Cosmatis, D; Gunderson, LL; Halberg, FE; Hanks, GR; Nagorney, DM; Noyes, RD, 1994) |
| " There remains the possibility that, on the basis of the combined drug dosage achieved, an increased therapeutic efficacy can be reached with either drug alone." | 2.67 | The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study. ( Bleehen, NM; Maughan, TS; Newman, HF; Stenning, S; Ward, R; Workman, P, 1991) |
| " Pharmacokinetic studies have shown the importance of area under the plasma drug concentration versus time curve (AUC) in predicting the risk of peripheral neuropathy." | 2.67 | Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508). ( Bleehen, NM; Maughan, TS; Newman, HF; Ward, R; Workman, P, 1990) |
| "H460 tumors showed higher tumor-to-muscle contrast in PET imaging; however, the distribution and uptake of the tracer was less specific for hypoxia in H460 than in HCT116 and PC3 tumors." | 1.40 | Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. ( Bida, GT; Chitneni, SK; Dewhirst, MW; Zalutsky, MR, 2014) |
| "In KHT tumors, perfused vessel numbers decreased significantly at 30 min post-hydralazine, then recovered somewhat by 60 min." | 1.31 | Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models. ( Fenton, BM, 2001) |
| "Necrosis was usually found adjacent to the highest level of binding in an individual patient's tumor." | 1.31 | Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. ( Evans, SM; Hahn, SM; Koch, CJ; Magarelli, DP, 2001) |
| " Plasma and urine pharmacokinetic studies showed that no drug interaction occurred." | 1.27 | A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics. ( Bleehen, NM; Newman, HF; Workman, P, 1986) |
| " There was no adverse pharmacokinetic interaction, or perturbation of plasma pharmacokinetics between initial and final infusions." | 1.27 | The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). ( Bleehen, NM; Newman, HF; Ward, R; Workman, P, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (36.36) | 18.7374 |
| 1990's | 8 (18.18) | 18.2507 |
| 2000's | 9 (20.45) | 29.6817 |
| 2010's | 10 (22.73) | 24.3611 |
| 2020's | 1 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Williams, EM | 3 |
| Rich, MH | 1 |
| Mowday, AM | 3 |
| Ashoorzadeh, A | 3 |
| Copp, JN | 3 |
| Guise, CP | 3 |
| Anderson, RF | 1 |
| Flanagan, JU | 2 |
| Smaill, JB | 3 |
| Patterson, AV | 3 |
| Ackerley, DF | 3 |
| Syddall, SP | 1 |
| Dubois, LJ | 1 |
| Wang, J | 1 |
| Lieuwes, NG | 1 |
| Biemans, R | 1 |
| Abbattista, MR | 1 |
| Lambin, P | 1 |
| Theys, J | 1 |
| Qian, Y | 1 |
| Von Eyben, R | 1 |
| Liu, Y | 2 |
| Chin, FT | 1 |
| Miao, Z | 1 |
| Apte, S | 1 |
| Carter, JN | 1 |
| Binkley, MS | 1 |
| Pollom, EL | 1 |
| Harris, JP | 1 |
| Prionas, ND | 1 |
| Kissel, M | 1 |
| Simmons, A | 1 |
| Diehn, M | 1 |
| Shultz, DB | 1 |
| Brown, JM | 4 |
| Maxim, PG | 1 |
| Koong, AC | 1 |
| Graves, EE | 1 |
| Loo, BW | 1 |
| Chitneni, SK | 2 |
| Bida, GT | 2 |
| Zalutsky, MR | 2 |
| Dewhirst, MW | 2 |
| Koch, CJ | 8 |
| Evans, SM | 7 |
| Sharrock, AV | 1 |
| He, F | 1 |
| Deng, X | 1 |
| Wen, B | 1 |
| Sun, X | 1 |
| Xing, L | 1 |
| Minami, A | 1 |
| Huang, Y | 1 |
| Chen, Q | 1 |
| Zanzonico, PB | 1 |
| Ling, CC | 1 |
| Li, GC | 1 |
| Minn, H | 2 |
| Grönroos, TJ | 2 |
| Komar, G | 1 |
| Eskola, O | 2 |
| Lehtiö, K | 1 |
| Tuomela, J | 1 |
| Seppänen, M | 1 |
| Solin, O | 2 |
| Abe, C | 1 |
| Uto, Y | 1 |
| Nakae, T | 1 |
| Shinmoto, Y | 1 |
| Sano, K | 1 |
| Nakata, H | 1 |
| Teraoka, M | 1 |
| Endo, Y | 1 |
| Maezawa, H | 1 |
| Masunaga, S | 1 |
| Nakata, E | 1 |
| Hori, H | 1 |
| Lin, LL | 1 |
| Silvoniemi, A | 1 |
| Stubbs, JB | 1 |
| Rengan, R | 1 |
| Suilamo, S | 1 |
| Divgi, C | 1 |
| Sorger, JM | 1 |
| Stabin, MG | 1 |
| Kachur, A | 1 |
| Hahn, SM | 3 |
| Forsback, S | 1 |
| Schrlau, AE | 1 |
| Chalian, AA | 1 |
| Zhang, P | 1 |
| Jin, C | 1 |
| Bai, L | 1 |
| Wu, H | 1 |
| Tian, F | 1 |
| Guo, G | 1 |
| Adams, GE | 1 |
| Urtasun, RC | 3 |
| Coleman, CN | 7 |
| Wasserman, TH | 4 |
| Phillips, TL | 2 |
| Williams, MV | 1 |
| Denekamp, J | 1 |
| Fowler, JF | 1 |
| Hancock, S | 2 |
| Harris, JW | 1 |
| Halsey, J | 2 |
| Hirst, VK | 1 |
| White, RA | 1 |
| Workman, P | 6 |
| Halberg, FE | 1 |
| Cosmatis, D | 1 |
| Gunderson, LL | 1 |
| Noyes, RD | 1 |
| Hanks, GR | 1 |
| Buswell, L | 2 |
| Nagorney, DM | 1 |
| Elias, AD | 1 |
| Wheeler, C | 1 |
| Ayash, LJ | 1 |
| Schwartz, G | 1 |
| Ibrahim, J | 1 |
| Mills, L | 1 |
| McCauley, M | 1 |
| Coleman, N | 1 |
| Warren, D | 1 |
| Schnipper, L | 1 |
| Antman, KH | 1 |
| Teicher, BA | 1 |
| Frei, E | 1 |
| Fenton, BM | 1 |
| Magarelli, DP | 1 |
| Rockwell, K | 1 |
| Covey, JM | 1 |
| McKenna, WG | 1 |
| Stratford, MR | 2 |
| Noll, L | 3 |
| Riese, N | 1 |
| Howes, AE | 2 |
| Loeffler, JS | 1 |
| Alexander, E | 1 |
| Wen, P | 1 |
| Harris, JR | 2 |
| Kramer, RA | 2 |
| Brown, TD | 1 |
| Burris, HA | 1 |
| Havlin, KA | 1 |
| O'Rourke, TJ | 1 |
| Rodriguez, GI | 1 |
| Wall, JG | 1 |
| Weiss, GR | 1 |
| Bleehen, NM | 5 |
| Maughan, TS | 3 |
| Newman, HF | 5 |
| Stenning, S | 1 |
| Ward, R | 3 |
| Zakar, J | 1 |
| Dische, S | 2 |
| Saunders, MI | 1 |
| Dunphy, EP | 1 |
| Bennett, MH | 1 |
| Des Rochers, C | 1 |
| Minchinton, AI | 1 |
| Orchard, RA | 1 |
| Mitchell, JB | 1 |
| McPherson, S | 1 |
| DeGraff, W | 1 |
| Gamson, J | 1 |
| Zabell, A | 1 |
| Russo, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study to Characterize the HRHV Axis in the Microenvironment of Breast Cancers[NCT01055678] | Early Phase 1 | 0 participants (Actual) | Interventional | 2010-01-31 | Withdrawn (stopped due to PI left Duke) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for etanidazole and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Imaging of tumor hypoxia to predict treatment sensitivity.
Topics: Animals; Cell Hypoxia; Drug Resistance, Neoplasm; Etanidazole; Humans; Hydrocarbons, Fluorinated; Ne | 2008 |
Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5.
Topics: Animals; Biochemistry; Etanidazole; Flow Cytometry; Humans; Hydrocarbons, Fluorinated; Hypoxia; Immu | 2002 |
Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles.
Topics: Animals; Cell Hypoxia; Etanidazole; Fluorine Radioisotopes; Humans; Hydrocarbons, Fluorinated; Model | 2003 |
Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?
Topics: Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Etanidazole; Hu | 1984 |
Pharmacokinetics and subcellular localization of radiosensitizers.
Topics: Etanidazole; Humans; Hydrogen-Ion Concentration; Misonidazole; Neoplasms; Nitroimidazoles; Radiation | 1992 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine | 1991 |
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione | 1985 |
Hypoxic cell radiosensitizers: expectations and progress in drug development.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Etanidazole; Humans; Metronidazole; Misonidazol | 1985 |
Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy.
Topics: Adrenal Cortex Hormones; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administra | 1985 |
15 trials available for etanidazole and Benign Neoplasms
| Article | Year |
|---|---|
Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?
Topics: Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Etanidazole; Hu | 1984 |
Dose-response relationships for human tumors: implications for clinical trials of dose modifying agents.
Topics: Animals; Clinical Trials as Topic; Dose-Response Relationship, Radiation; Etanidazole; Humans; Mice; | 1984 |
RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies.
Topics: Adolescent; Adult; Aged; Cell Hypoxia; Combined Modality Therapy; Etanidazole; Evaluation Studies as | 1994 |
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Disease-Free Survi | 1998 |
Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Topics: Area Under Curve; Body Weight; Chromatography, High Pressure Liquid; Etanidazole; Half-Life; Humans; | 2001 |
Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
Topics: Brachytherapy; Combined Modality Therapy; Drug Evaluation; Etanidazole; Female; Humans; Infusions, I | 1992 |
The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.
Topics: Adult; Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Combinations; Etanida | 1991 |
Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
Topics: Aged; Clinical Trials as Topic; Etanidazole; Humans; Male; Middle Aged; Neoplasms; Nitroimidazoles; | 1990 |
Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Topics: Adult; Canada; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Infusions, Intraveno | 1990 |
Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
Topics: Brachytherapy; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Infusions, Intraveno | 1989 |
A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Topics: Drug Combinations; Etanidazole; Humans; Neoplasms; Nitroimidazoles; Peripheral Nervous System Diseas | 1989 |
Hypoxic cell radiosensitizers: illusion or elusion?
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Etanidazole; Humans; Neoplasms; Nitroimidazoles | 1988 |
Sensitizers and protectors in radiotherapy.
Topics: Amifostine; Animals; Aziridines; Clinical Trials as Topic; Drug Evaluation; Etanidazole; Glutathione | 1985 |
Hypoxic cell radiosensitizers: expectations and progress in drug development.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Etanidazole; Humans; Metronidazole; Misonidazol | 1985 |
Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy.
Topics: Adrenal Cortex Hormones; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administra | 1985 |
23 other studies available for etanidazole and Benign Neoplasms
| Article | Year |
|---|---|
Engineering
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Hypoxia; Drug Monitoring; Enzyme Activation; Esch | 2019 |
Topics: Animals; Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Escherichia coli Proteins; Et | 2020 |
Topics: Aged; Aged, 80 and over; Etanidazole; Female; Fluorine Radioisotopes; Humans; Hydrocarbons, Fluorina | 2018 |
Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Topics: Animals; Benzimidazoles; Biological Transport; Cell Hypoxia; Cell Line, Tumor; Cell Transformation, | 2014 |
Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding.
Topics: Animals; Cell Transformation, Neoplastic; Etanidazole; Fluorine Radioisotopes; Humans; Hydrocarbons, | 2015 |
Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding.
Topics: Animals; Cell Transformation, Neoplastic; Etanidazole; Fluorine Radioisotopes; Humans; Hydrocarbons, | 2015 |
Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
Topics: Binding Sites; Cell Line, Tumor; Escherichia coli; Escherichia coli Proteins; Etanidazole; HCT116 Ce | 2017 |
Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers.
Topics: Animals; Antigens, Neoplasm; Arabinofuranosyluracil; Autoradiography; Biomarkers; Carbonic Anhydrase | 2008 |
Evaluation of the in vivo radiosensitizing activity of etanidazole using tumor-bearing chick embryo.
Topics: Animals; Antineoplastic Agents; Chick Embryo; Chorioallantoic Membrane; Disease Models, Animal; Dose | 2011 |
In regard to Brown et al. (Int J Radiat Oncol Biol Phys 2010;78:323-327).
Topics: Brain Neoplasms; Cell Hypoxia; Etanidazole; Humans; Neoplasms; Radiation-Sensitizing Agents | 2011 |
Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients.
Topics: Adult; Cell Hypoxia; Dose-Response Relationship, Radiation; Etanidazole; Female; Fluorine Radioisoto | 2012 |
Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding.
Topics: Aged; Antibodies, Monoclonal; Dermis; Etanidazole; Female; Fluorescence; Humans; Hydrocarbons, Fluor | 2006 |
Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Chromatography, Hi | 2007 |
Clinical perspectives for the use of new hypoxic cell sensitizers.
Topics: Animals; Cyclophosphamide; Dogs; Drug Therapy, Combination; Etanidazole; Humans; Melphalan; Mice; Mi | 1982 |
Radiosensitizers: a conference preview.
Topics: Animals; Aziridines; Buthionine Sulfoximine; Carmustine; Combined Modality Therapy; Drug Synergism; | 1984 |
Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
Topics: Drug Evaluation; Etanidazole; Humans; Neoplasms; Nitroimidazoles; Radiation-Sensitizing Agents; Time | 1984 |
The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
Topics: Administration, Oral; Animals; Biological Availability; Dog Diseases; Dogs; Drug Evaluation, Preclin | 1980 |
Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models.
Topics: Animals; Carbocyanines; Cell Hypoxia; Etanidazole; Female; Fibrosarcoma; Fluorescent Dyes; Hydralazi | 2001 |
Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation.
Topics: Antineoplastic Agents; Cell Division; Cell Hypoxia; Clinical Trials, Phase I as Topic; Etanidazole; | 2001 |
A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Drug Combinations; Drug Evaluation; Etanidazole; | 1986 |
Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
Topics: Aged; Etanidazole; Female; Humans; Male; Middle Aged; Misonidazole; Neoplasms; Nitroimidazoles; Radi | 1986 |
The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Topics: Adult; Aged; Combined Modality Therapy; Drug Therapy, Combination; Etanidazole; Humans; Middle Aged; | 1988 |
Oxygen dependence of hematoporphyrin derivative-induced photoinactivation of Chinese hamster cells.
Topics: Animals; Cell Line; Cell Survival; Cricetinae; Cricetulus; Etanidazole; Hematoporphyrins; Neoplasms; | 1985 |